[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355372-105":59,"doc-detail-355372-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rgx-019-mmae-inhibits-leukemia-progression-research-open-access","RGX-019-MMAE inhibits leukemia progression - Research open access","","MERTK (MER proto-oncogene tyrosine kinase) is overexpressed in cancers and correlates with poor outcomes, particularly in acute myeloid leukemia (AML). RGX-019-MMAE is a humanized IgG1 antibody-drug conjugate that binds MERTK, triggers internalization and receptor degradation, and releases MMAE to disrupt mitosis. Reverse-phase protein arrays in 818 AML patients identify high MERTK in monocytic AML subsets, and dose-dependent effects include increased leukemic killing, inhibited progression, and improved xenograft survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rgx-019-mmae-inhibits-leukemia-progression-research-open-access/355372/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rgx-019-mmae-inhibits-leukemia-progression-research-open-access/355372.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is RGX-019-MMAE and what does it target in AML?","Question",{"text":112,"@type":113},"RGX-019-MMAE is a humanized IgG1 antibody-drug conjugate designed to selectively bind the MERTK receptor in acute myeloid leukemia. Binding leads to internalization and degradation of MERTK, enabling payload release.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was MERTK expression evaluated in the study?",{"text":117,"@type":113},"MERTK protein expression was assessed in 818 AML patients using reverse-phase protein arrays (RPPA). Expression was also measured by flow cytometry in AML cell lines and in peripheral blood or bone marrow mononuclear cells from additional AML patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key biological and therapeutic outcomes of RGX-019-MMAE treatment?",{"text":121,"@type":113},"RGX-019-MMAE caused dose-dependent leukemic cell killing and inhibited AML progression. It also prolonged survival in AML xenograft-bearing mice and sensitized AML cells to venetoclax, while showing no effect on normal hematopoietic stem cell clonogenic potential.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355372,1790153337,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Tyagi etal. Journal of Experimental & Clinical Cancer Research (2026) 45:81 [https://doi.org/10.1186/s13046-026-03657-y](https://doi.org/10.1186/s13046-026-03657-y)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nRGX-019-MMAE inhibits leukemia progression  by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia  \nAnudishiTyagi1,3†, Maryam Siddiqui1†, Amanda Eckstrom 1, Isabel Kurth2, Shugaku Takeda2†, Priyanka Sharma1, Gautam Borthakur1, Bin Yuan1, Hussein A. Abbas 1, Vivek Anand1, Jenny Borgman1, Steven Kornblau 1, Abhishek Maiti1 and V. Lokesh Battula 1,3*  \nAbstract  \nBackground Myeloid epithelial reproductive tyrosine kinase (MERTK) receptor is overexpressed in cancers and is associated with poor prognosis. RGX-019-MMAE, a novel humanized IgG1-MMAE antibody-drug conjugate (ADC)(Inspirna, Inc), selectively binds to MERTK with high affinity, resulting in internalization and degradation of the receptor. It then induces cytotoxicity through the release of the payload, MMAE (monomethyl auristatin E), which disrupts mitosis.  \nMethods MERTK protein expression was analyzed in 818 AML patients using Reverse Phase Protein Arrays (RPPA) . Expression was also assessed by flow cytometry in eight AML cell lines and peripheral blood or bone marrow mononuclear cells from five AML patients. Cell lines with the highest MERTK expression were treated with varying doses of RGX-019-MMAE or naked antibody for 120 h, and viability was measured using CellTiter-Glo 2.0. Similarly, primary cells from five AML patients were treated to assess the anti-leukemic effect of RGX-019-MMAE. Further, the combinatorial effects of RGX-019-MMAE with venetoclax (BCL2 inhibitor) were evaluated in vitro.  \nResults Reverse-phase protein array in 818 primary AML samples revealed significantly high MERTK protein expression in monocytic acute myeloid leukemia (AML), especially in those with PTPN11, RAS, CEBPA mutations, t (9;11) translocation, and high WBC count, suggesting its potential as a therapeutic target in AML. We also observed varying degrees of MERTK expression in AML cell lines, with highest expression in Kasumi-1 and OCI-AML3 . Treatment of these cell lines with the anti-MERTK antibody-drug conjugate RGX-019-MMAE resulted in significantly more leukemic cell killing than the control antibody in a dose-dependent manner. We validated this finding in MERTK-expressing primary AML samples expressing MERTK. Interestingly, RGX-019-MMAE had no effect on normal hematopoietic stem cells’ clonogenic potential. Further, treatment with RGX-019-MMAE inhibited AML progression  \n†AnudishiTyagi, Maryam Siddiqui and Shugaku Takeda contributed equally to this work.  \n*Correspondence:  \nV. Lokesh Battula [battulav3@vcu.edu](battulav3@vcu.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026, modified publication 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons](http://creativecommons). org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this","cbCaioAf4AK4XmfF","https://ap.wps.com/l/cbCaioAf4AK4XmfF","pdf",3319374,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Additional context","[{\"question\":\"What is RGX-019-MMAE and what does it target in AML?\",\"answer\":\"RGX-019-MMAE is a humanized IgG1 antibody-drug conjugate designed to selectively bind the MERTK receptor in acute myeloid leukemia. Binding leads to internalization and degradation of MERTK, enabling payload release.\"},{\"question\":\"How was MERTK expression evaluated in the study?\",\"answer\":\"MERTK protein expression was assessed in 818 AML patients using reverse-phase protein arrays (RPPA). Expression was also measured by flow cytometry in AML cell lines and in peripheral blood or bone marrow mononuclear cells from additional AML patients.\"},{\"question\":\"What were the key biological and therapeutic outcomes of RGX-019-MMAE treatment?\",\"answer\":\"RGX-019-MMAE caused dose-dependent leukemic cell killing and inhibited AML progression. It also prolonged survival in AML xenograft-bearing mice and sensitized AML cells to venetoclax, while showing no effect on normal hematopoietic stem cell clonogenic potential.\"}]","RGX-019-MMAE inhibits leukemia progression - Research open access | PDF",1790118153,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd8c12b050cc6c5a3c45cb8e71dcd47a.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb7afd60ec42591da91bb0df7525f299.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/321c320cdb4815e84a676a8b88528648.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/144f546d16a9605cf6927f00489e579a.webp",980,1306]